Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of AMG 570 in active systemic lupus erythematosus with inadequate response to standard of care
2019-000328-16Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of rozibafusp alfa in systemic lupus erythematosus (SLE), sponsored by Amgen. Primary endpoint: SRI-4 response at week 24. Started Jul 2019; status: completed.
02
Drugs
rozibafusp alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2019-000328-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000328-16.